Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO GI 2021 | Updates in the use of neratinib in fibrolamellar carcinoma and biliary tract cancer

Ghassan Abou-Alfa • 21 Jan 2021
ASCO GI 2021
Bile Duct Cancer Gastrointestinal Cancer Everolimus Neratinib Nivolumab Pembrolizumab
SUMMIT

Ghassan Abou-Alfa, MD, Memorial Sloan-Kettering Cancer Center, New York City, NY, updates us on the use of neratinib in both fibrolamellar carcinoma and biliary tract cancer, the latter of which where neratinib was evaluated in combination with immune checkpoint blockade.This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

More from Ghassan Abou-Alfa

2:19
Should HCC be treated with locoregional or systemic therapies?
Ghassan Abou-Alfa • 22 Jun 2023
2:32
The role of systemic treatment in early-stage hepatocellular carcinoma
Ghassan Abou-Alfa • 22 Jun 2023
1:53
SCG101: a novel T-cell therapy in advanced hepatitis B-related HCC
Ghassan Abou-Alfa • 22 Jun 2023
3:52
What role does TIGIT inhibition have in treating hepatocellular carcinoma?
Ghassan Abou-Alfa • 22 Jun 2023

Related Videos

1:53
Important pathophysiological determinants of elevated cirDNA post-surgery
Alain Thierry • 9 Apr 2024
0:47
Emerging molecular drivers and biomarker targets in gastroesophageal cancers
Tatsuhiro Shibata • 9 Apr 2024
0:52
DRP-104 with durvalumab in fibrolamellar hepatocellular carcinoma
Marina Baretti • 9 Apr 2024
1:06
The emerging role of cancer vaccines in treating liver cancer
Marina Baretti • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals